William Blair & Company
CRL icon

William Blair & Company’s Charles River Laboratories CRL Stock Holding History

William Blair & Company’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$586K Sell
2,583
-1,992
-44% -$355K ﹤0.01% 1169
2026
Q1 		$789K Buy
+4,575
New +$848K ﹤0.01% 1015
2025
Q1 		– Sell
-1,600
Closed -$295K – 1820
2024
Q4 		$295K Sell
1,600
-76
-5% -$14.6K ﹤0.01% 1293
2024
Q3 		$330K Buy
1,676
+4
+0.2% +$831 ﹤0.01% 1255
2024
Q2 		$345K Sell
1,672
-1,755
-51% -$398K ﹤0.01% 1219
2024
Q1 		$929K Sell
3,427
-37
-1% -$8.84K ﹤0.01% 894
2023
Q4 		$819K Sell
3,464
-138
-4% -$27.1K ﹤0.01% 921
2023
Q3 		$706K Sell
3,602
-326
-8% -$66.9K ﹤0.01% 952
2023
Q2 		$826K Sell
3,928
-174
-4% -$34.6K ﹤0.01% 908
2023
Q1 		$828K Sell
4,102
-1,002
-20% -$227K ﹤0.01% 887
2022
Q4 		$1.11M Buy
5,104
+213
+4% +$46.5K ﹤0.01% 793
2022
Q3 		$963K Sell
4,891
-1,449
-23% -$313K ﹤0.01% 825
2022
Q2 		$1.36M Sell
6,340
-3,334
-34% -$815K 0.01% 743
2022
Q1 		$2.75M Sell
9,674
-550
-5% -$170K 0.01% 616
2021
Q4 		$3.85M Sell
10,224
-5,012
-33% -$1.95M 0.01% 551
2021
Q3 		$6.29M Buy
15,236
+116
+0.8% +$48.2K 0.02% 412
2021
Q2 		$5.59M Sell
15,120
-165
-1% -$55.1K 0.02% 435
2021
Q1 		$4.43M Buy
15,285
+5,552
+57% +$1.54M 0.02% 475
2020
Q4 		$2.43M Buy
9,733
+4,198
+76% +$1,000K 0.01% 598
2020
Q3 		$1.25M Buy
5,535
+76
+1% +$15.8K 0.01% 693
2020
Q2 		$952K Buy
5,459
+284
+5% +$45.3K ﹤0.01% 729
2020
Q1 		$653K Buy
5,175
+33
+0.6% +$4.95K ﹤0.01% 796
2019
Q4 		$785K Buy
+5,142
New +$712K ﹤0.01% 849
2018
Q3 		– Sell
-2,779
Closed -$312K – 1624
2018
Q2 		$312K Sell
2,779
-43
-2% -$4.65K ﹤0.01% 1102
2018
Q1 		$301K Buy
2,822
+829
+42% +$89.4K ﹤0.01% 1071
2017
Q4 		$218K Buy
+1,993
New +$217K ﹤0.01% 1242

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

William Blair & Company's CRL Position: Q2 2026 in Review

William Blair & Company reduced its Charles River Laboratories (CRL) stake by 44% in Q2 2026, selling an estimated $355K and leaving 2,583 shares worth $586K. The position accounts for ﹤0.01% of the portfolio, ranked #1169.

William Blair & Company first reported a position in CRL in Q4 2017 and has held it in 26 quarters since. The position peaked at $6.29M in Q3 2021. 569 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • William Blair & Company held 2,583 shares of Charles River Laboratories worth $586K as of Q2 2026.
  • William Blair & Company sold 1,992 Charles River Laboratories shares in Q2 2026, an estimated $355K.
  • Charles River Laboratories made up ﹤0.01% of William Blair & Company's portfolio in Q2 2026, its #1169 holding.
  • William Blair & Company first reported a position in Charles River Laboratories in Q4 2017 and has held it in 26 quarters since.
  • William Blair & Company's Charles River Laboratories position peaked at $6.29M in Q3 2021.
  • 569 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on William Blair & Company's 13F filing for Q2 2026, filed 11 Aug 2026.